Depreciation of CRISPR Therapeutics AG from 31 Dec 2014 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
CRISPR Therapeutics AG quarterly and annual Depreciation in USD history and change rate from 31 Dec 2014 to 31 Dec 2025.
  • CRISPR Therapeutics AG Depreciation for the quarter ending 31 Dec 2025 was $5,700,000, a 19% increase year-over-year.
  • CRISPR Therapeutics AG Depreciation for the twelve months ending 31 Dec 2025 was $19,400,000, a 1% increase year-over-year.
  • CRISPR Therapeutics AG annual Depreciation for 2025 was $19,400,000, a 1% increase from 2024.
  • CRISPR Therapeutics AG annual Depreciation for 2024 was $19,200,000, a 3% decline from 2023.
  • CRISPR Therapeutics AG annual Depreciation for 2023 was $19,800,000, a 18% decline from 2022.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

CRISPR Therapeutics AG Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $19,400,000 $5,700,000 +$900,000 +19% 01 Oct 2025 31 Dec 2025 10-K 12 Feb 2026 2025 FY
Q3 2025 $18,500,000 $4,400,000 -$400,000 -8.3% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $18,900,000 $4,600,000 -$200,000 -4.2% 01 Apr 2025 30 Jun 2025 10-Q 04 Aug 2025 2025 Q2
Q1 2025 $19,100,000 $4,700,000 -$100,000 -2.1% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $19,200,000 $4,800,000 -$100,000 -2% 01 Oct 2024 31 Dec 2024 10-K 12 Feb 2026 2025 FY
Q3 2024 $19,300,000 $4,800,000 -$100,000 -2% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $19,400,000 $4,800,000 -$200,000 -4% 01 Apr 2024 30 Jun 2024 10-Q 04 Aug 2025 2025 Q2
Q1 2024 $19,600,000 $4,800,000 -$200,000 -4% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $19,800,000 $4,900,000 -$900,000 -16% 01 Oct 2023 31 Dec 2023 10-K 12 Feb 2026 2025 FY
Q3 2023 $20,700,000 $4,900,000 -$100,000 -2% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $20,800,000 $5,000,000 -$2,300,000 -32% 01 Apr 2023 30 Jun 2023 10-Q 05 Aug 2024 2024 Q2
Q1 2023 $23,100,000 $5,000,000 -$1,000,000 -17% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $24,100,000 $5,800,000 -$500,000 -7.9% 01 Oct 2022 31 Dec 2022 10-K 11 Feb 2025 2024 FY
Q3 2022 $24,600,000 $5,000,000 -$300,000 -5.7% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $24,900,000 $7,300,000 +$3,700,000 +103% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $21,200,000 $6,000,000 +$3,300,000 +122% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $17,900,000 $6,300,000 +$3,800,000 +152% 01 Oct 2021 31 Dec 2021 10-K 21 Feb 2024 2023 FY
Q3 2021 $14,100,000 $5,300,000 +$3,000,000 +130% 01 Jul 2021 30 Sep 2021 10-Q 01 Nov 2022 2022 Q3
Q2 2021 $11,100,000 $3,600,000 +$1,400,000 +64% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $9,700,000 $2,700,000 +$600,000 +29% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $9,100,000 $2,500,000 +$1,100,000 +79% 01 Oct 2020 31 Dec 2020 10-K 21 Feb 2023 2022 FY
Q3 2020 $8,000,000 $2,300,000 +$1,000,000 +77% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $7,000,000 $2,200,000 +$1,200,000 +120% 01 Apr 2020 30 Jun 2020 10-Q 29 Jul 2021 2021 Q2
Q1 2020 $5,800,000 $2,100,000 +$1,100,000 +110% 01 Jan 2020 31 Mar 2020 10-Q 27 Apr 2021 2021 Q1
Q4 2019 $4,700,000 $1,400,000 +$400,000 +40% 01 Oct 2019 31 Dec 2019 10-K 15 Feb 2022 2021 FY
Q3 2019 $4,300,000 $1,300,000 +$500,000 +62% 01 Jul 2019 30 Sep 2019 10-Q 28 Oct 2020 2020 Q3
Q2 2019 $3,800,000 $1,000,000 +$100,000 +11% 01 Apr 2019 30 Jun 2019 10-Q 27 Jul 2020 2020 Q2
Q1 2019 $3,700,000 $1,000,000 +$200,000 +25% 01 Jan 2019 31 Mar 2019 10-Q 28 Apr 2020 2020 Q1
Q4 2018 $3,500,000 $1,000,000 +$200,000 +25% 01 Oct 2018 31 Dec 2018 10-K 16 Feb 2021 2020 FY
Q3 2018 $3,300,000 $800,000 $0 0% 01 Jul 2018 30 Sep 2018 10-Q 28 Oct 2019 2019 Q3
Q2 2018 $3,300,000 $900,000 +$200,000 +29% 01 Apr 2018 30 Jun 2018 10-Q 29 Jul 2019 2019 Q2
Q1 2018 $3,100,000 $800,000 +$100,000 +14% 01 Jan 2018 31 Mar 2018 10-Q 29 Apr 2019 2019 Q1
Q4 2017 $3,000,000 $800,000 +$300,000 +60% 01 Oct 2017 31 Dec 2017 10-K 12 Feb 2020 2019 FY
Q3 2017 $2,700,000 $800,000 +$600,000 +300% 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2018 Q3
Q2 2017 $2,100,000 $700,000 +$600,000 +600% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $1,500,000 $700,000 +$600,000 +600% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 $900,000 $500,000 01 Oct 2016 31 Dec 2016 10-K 25 Feb 2019 2018 FY
Q3 2016 $200,000 +$173,000 +641% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q2 2016 $100,000 01 Apr 2016 30 Jun 2016 10-Q 10 Aug 2017 2017 Q2
Q1 2016 $100,000 01 Jan 2016 31 Mar 2016 10-Q 11 May 2017 2017 Q1
Q3 2015 $27,000 01 Jul 2015 30 Sep 2015 10-Q 22 Nov 2016 2016 Q3

CRISPR Therapeutics AG Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $19,400,000 +$200,000 +1% 01 Jan 2025 31 Dec 2025 10-K 12 Feb 2026 2025 FY
2024 $19,200,000 -$600,000 -3% 01 Jan 2024 31 Dec 2024 10-K 12 Feb 2026 2025 FY
2023 $19,800,000 -$4,300,000 -18% 01 Jan 2023 31 Dec 2023 10-K 12 Feb 2026 2025 FY
2022 $24,100,000 +$6,200,000 +35% 01 Jan 2022 31 Dec 2022 10-K 11 Feb 2025 2024 FY
2021 $17,900,000 +$8,800,000 +97% 01 Jan 2021 31 Dec 2021 10-K 21 Feb 2024 2023 FY
2020 $9,100,000 +$4,400,000 +94% 01 Jan 2020 31 Dec 2020 10-K 21 Feb 2023 2022 FY
2019 $4,700,000 +$1,200,000 +34% 01 Jan 2019 31 Dec 2019 10-K 15 Feb 2022 2021 FY
2018 $3,500,000 +$500,000 +17% 01 Jan 2018 31 Dec 2018 10-K 16 Feb 2021 2020 FY
2017 $3,000,000 +$2,100,000 +233% 01 Jan 2017 31 Dec 2017 10-K 12 Feb 2020 2019 FY
2016 $900,000 +$800,000 +800% 01 Jan 2016 31 Dec 2016 10-K 25 Feb 2019 2018 FY
2015 $100,000 +$100,000 01 Jan 2015 31 Dec 2015 10-K 08 Mar 2018 2017 FY
2014 $0 01 Jan 2014 31 Dec 2014 10-K 10 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.